Ultimovacs is a pharmaceutical company developing immunotherapies against cancer. Its lead product candidate is UV1, a peptide-based vaccine that induces a specific T-cell response against the universal cancer antigen telomerase. The company merged with Zelluna Immunotherapy to form Zelluna.